Last updated: December 7, 2022
Sponsor: Samyang Biopharmaceuticals Corporation
Overall Status: Active - Recruiting
Phase
N/A
Condition
N/ATreatment
N/AClinical Study ID
NCT05645809
MF_PGCL_401
Ages > 19 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients scheduled for hysterectomy by laparoscopic surgery
- Patients who are scheduled to undergo hysterectomy after being diagnosed with benigntumors in the uterus, including uterine myoma, according to the medical judgment ofthe investigator
- Laparoscopic surgery includes general laparoscopic surgery and robotic surgery.)
Exclusion
Exclusion Criteria:
- Patients with contaminated wounds
- Diseases that may affect wound healing
- When gynecological malignancy or intra-abdominal metastasis is confirmed at the timeof enrollment
Study Design
Total Participants: 98
Study Start date:
November 03, 2022
Estimated Completion Date:
September 30, 2023
Connect with a study center
Korea University Guro Hospital
Seoul,
Korea, Republic ofActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.